Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1997-12-01
2000-08-01
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
5142362, 514278, 514329, A61K 31675, A61K 31535, A61K 3144, A61K 31445
Patent
active
060967293
ABSTRACT:
The present invention provides methods for the treatment or prevention of amnestic disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
REFERENCES:
patent: 5162339 (1992-11-01), Lowe, III
patent: 5496833 (1996-03-01), Baker et al.
patent: 5538982 (1996-07-01), Hagan et al.
patent: 5612337 (1997-03-01), Baker et al.
patent: 5716942 (1998-02-01), Dorn et al.
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5728695 (1998-03-01), Harrison et al.
Aguiar, M., et al., Physiology & Behavior, 1996, 60 (4) 1183-1186.
Barden, N., et al., J. Neurochem., 1983, 41, 834-840.
Brodin, E., et al., Neuropharmacology, 1987, 26 (6) 581-590.
Brodin, E., et al., Neuropeptides, 1994, 26, 253-260.
Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885-891.
Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87.
Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354-356.
F-D-C Reports--Prescription Pharmaceuticals and Biotechnology, Dec. 8, 1997, 59 (49), 10.
File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747-752.
Kramer, et al., Science, 1998, 281, 1640-1645.
Lowe, J., et al., Drug News Perspect, 1992, 5 (4), 223.
Malek-Ahmadi, Neuroscience and Behavioral Reviews, 1992, 16, 365-359.
Rimon, R., et al., Biological Psychiatry, 1984, 19 (4), 509-516.
Roccon, et al., Pharmacological Research, 1995, 31, 191.
Shaikh, M., et al., Brain Research, 1993, 625, 283-294.
Shirayama, Y., et al., Brain Research, 1996, 739, 70-78.
Siegel, R., et al., Neurochem. Int., 1984, 6 (6), 783-789.
Siegel, A., et al., Aggressive Behavior, 1995, 21, 49-62.
Teixeira, R., et al., European J. Pharm., 1996, 311, 7-14.
Vassout, et al., Neuropeptides, 1994, 26 (Suppl. 1), 38.
Wahlestedt, Science, 1998, 281, 1624-1625.
Wall Street Journal, Aug. 13, 1998, B1, col. 2.
Baker Raymond
Curtis Neil Roy
Elliott Jason Matthew
Harrison Timothy
Hollingworth Gregory John
Jarvis William R. A.
Merck Sharp & Dohme Ltd.
Rose David L.
Thies J. Eric
LandOfFree
Use of NK-1 receptor antagonists for treating amnestic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of NK-1 receptor antagonists for treating amnestic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of NK-1 receptor antagonists for treating amnestic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-664032